A Phase 1/2 interventional study of AL-001 in Wet Age-related Macular Degeneration (wAMD), sponsored by Beijing Anlong Biopharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Beijing Anlong Biopharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.
Among the 106 studies in Macular Degeneration with a site in China, this one is the 73rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2023, is one of 18 in phase 1/2, reaches primary completion later than 8 of the 42 other live ones, and was the 82nd registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 50–85
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 16 more countries
Ages 50+
Innostellar Biotherapeutics Co.,Ltd · Sites in China
Ages 50–80
Innovent Biologics Technology Limited (Shanghai R&D Center) · Sites in China
Ages 50+
Peking University People's Hospital · Sites in China
Ages 50+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 36 · Phase 3 22 · Phase 4 5
First in 2008; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 62 across the 91 interventional studies, 300 across the 15 observational. Of the 39 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 106 have an industry lead sponsor. The 10 most frequent:
Beijing Anlong Biopharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Beijing Anlong Biopharmaceutical Co., Ltd. has 3 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Degeneration with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972473Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD | 2027-02-28 |
| NCT07189169Phase 3Smilebiotek Zhuhai LimitedQA108 Phase III Study in Subjects With Intermediate AMD | 2027-03-01 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT07053358Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | 2026-11-23 |
| NCT07409389The Hong Kong Polytechnic UniversityRepeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration | 2026-12-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 106 studies in Macular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase I/IIa study is designed to evaluate the safety, tolerability, preliminary pharmacodynamics and pharmacokinetics in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will receive a single dose of AL-001 administered via suprachoroidal space injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Injection of low dose
Drug: AL-001
Injection of medium dose
Drug: AL-001
Injection of high dose
Drug: AL-001
Administered via suprachoroidal space injection.
Safety and tolerability
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time frame: Week 24
Evaluate the effect of AL-001 on BCVA
Mean change from baseline in BCVA
Time frame: Week 52
Started Sep 2023 (actual). Primary completion is estimated for Aug 2025, 23 months after the start.
Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latozinemab
Beijing Anlong Biopharmaceutical Co., Ltd.